uploads///Chart

How Novartis’s Revenues Trended in 4Q17

By

Mar. 13 2018, Updated 5:40 p.m. ET

Novartis’s revenues in 4Q17

Novartis (NVS) reported 5% growth in revenues to ~$12.9 billion during 4Q17 as compared to ~$12.3 billion during 4Q16. The below chart compares revenues for Novartis since 1Q16.

Article continues below advertisement

4Q17 revenues

Novartis surpassed Wall Street analysts’ estimates for earnings per share (or EPS) with posted EPS of $1.21 as compared to the estimates of $1.19 during 4Q17. Novartis also surpassed analysts’ estimates for revenues with reported revenues of ~$12.9 billion as compared to the estimates of ~$12.8 billion during 4Q17. The revenues increased by ~5% including a 2% growth in operating revenues and a 3% favorable impact of foreign exchange during 4Q17.

The US sales reported a 1% decline to ~$4.3 billion during 4Q17 as compared to ~$4.4 billion during 4Q16. European markets saw an 8% increase in sales to ~$4.7 billion during 4Q17, as compared to ~$4.3 billion during 4Q16. The Canada and Latin America markets saw a 7% increase in sales to ~$1.0 billion during 4Q17, as compared to $963 million during 4Q16. The Asia/Africa/Australasia markets saw a ~8% increase in sales to ~$2.9 billion during 4Q17 as compared to ~$2.6 billion during 4Q16.

Article continues below advertisement

2017 revenues

Novartis surpassed Wall Street analysts’ estimates for earnings per share (or EPS) with reported EPS of $4.86 as compared to estimates of $4.82 for 2017. However, Novartis missed the revenue estimates for 2017 and reported revenues of ~$49.1 billion as compared to the estimates of ~$49.2 billion during 2017. The revenues increased by ~1% during 2017, including a 2% growth in operating revenues, offset by a ~1% negative impact of foreign exchange.

The US sales reported a 1% decline to ~$16.9 billion during 2017 as compared to ~$17.1 billion during 2016. European markets saw a 2% growth in revenues to ~$17.5 billion during 2017 as compared to ~$17.1 billion during 2016. Sales from Canada and Latin America markets reported 2% growth to ~$4.0 billion during 2017 as compared to $3.9 billion during 2016. The Asia/Africa/Australasia markets reported a ~3% increase in sales to ~$10.7 billion during 2017 as compared to ~$10.4 billion during 2016.

The First Trust Value Line Dividend ETF (FVD) holds 6.3% of its total investments in healthcare companies. FVD holds 0.5% in Novartis (NVS), 0.5% in GlaxoSmithKline (GSK), 0.5% in Merck (MRK), and 0.5% in Bristol-Myers Squibb (BMY).

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.